Roivant Sciences Ltd. (ROIV) — Fair Value Analysis

Base-case fair value (P50): $32.95 · Current price: $35.12 · Verdict: Fairly Valued

The Verdict on ROIV

Our Monte Carlo simulations indicate ROIVANT SCIENCES LTD (ROIV) is currently Fairly Valued. At a $35.12 per share, ROIV trades near our P50 median fair value of $32.95. This suggests an -6.2% against the current market price, positioning ROIV without a significant premium or discount based on our quantitative models. The robust simulation, incorporating thousands of forward-looking scenarios, points to a balanced valuation for the company at present.

How ROIV stacks up against peers

Despite the Fairly Valued verdict, ROIV’s operational and financial health is categorized as weak compared to its peers. While not assigned to a specific sector in our analysis, this weak quality tier signals potential underlying concerns about ROIV’s fundamentals relative to broader market participants. Investors should weigh the implications of this quality tier alongside the current fair value assessment. The $35.12 reflects a market perception aligned with its intrinsic value, but the quality tier suggests a need for careful consideration of ROIV's competitive standing and risk profile.

What this means for investors

For investors tracking ROIV, the $35.12 and its proximity to our $32.95 median fair value offer a neutral stance. The -6.2% figure reinforces the Fairly Valued verdict, indicating that our models do not detect a compelling mispricing. Given the weak quality tier, any significant downside scenario could present challenges, while upside scenarios would require a re-evaluation of its operational strength. To understand the full distribution of potential outcomes, including the specific bear and bull case targets and the probability of upside, sign up for a free FairCurve account.